BENGALURU: A device designed by an Indian scientist to contain the infectivity of SARS-CoV-2 — Scalene Hypercharge Corona Canon (SHYCOCAN) — has now got clearances from regulatory agencies in the US and EU for production under emergency use against Covid-19.
Its inventor, Rajah Vijay Kumar, told TOI: “In the US, Emergo, the notified body under US-FDA that clears medical devices, has given us permission for production and marketing. We’ve also successfully completed extensive European Union CE- mandated safety testing undertaken by the Underwriters Laboratories and obtained the class-I CE Mark, enabling expedited manufacture, distribution, and sales in all CE-compliant countries, including India.”

CE stands for “Conformité Européene” meaning European Conformity. It is a mandatory certification required for any product to be sold in the EU.
SHYCOCAN is a device that emits photons that can disarms the virus.
Kumar said Organization de Scalene-India, where he heads research, will now fast-track manufacture and distribution of the CE-marked SHYCOCAN under US-FDA ‘Enforcement Policy for containment of SARS-COV2 During the Covid-19 Public Health Emergency’.
The technology, he said, is intended to ‘physically attenuate’ the homing mechanism on the virus and prevent infectivity. TOI was the first to report in March that SHYCOCAN, which had demonstrated its ability to reduce infectivity of other coronaviruses, was to be tested specifically for Covid-19 in the US.

The device is designed to release a very high concentration of environmentally safe electrons using proprietary Photon-Mediated Electron Emitters (PMEEs) made with a superalloy developed by Scalene, to emit and excite photons with the required kinetic energy.
“As the high energy photons bombard bulk surfaces and suspended particles in confined environments, the electron cloud actively ‘disarms’ air and surface transmission of the Corona family of viruses,” Kumar added.
Stating that the device targets only the Corona family of viruses, he said, laboratory studies show that bacteria, fungi or other eco-friendly microorganisms are not targeted by this technology, allowing for 24/7, safe deployment.

The phased deployment of the SHYCOCAN is being discussed with top tier global manufacturing companies for mass production and distribution. Many leading companies in India, US, Europe and South Africa have already started to plan mass manufacturing and deployment under ‘humanitarian technology license from Organization de Scalene.
“Today, this is the only experimentally proven technology with straight virologic, bacteriological and fungal studies. SHYCOCAN and will help create ‘safer zones’ in homes, healthcare facilities, grocery chains, eateries, schools, daycares, places of worship, and residential, corporate, industrial and sporting environments, to fill unmet needs, without affecting other life forms like bacteria, fungi, plants and animals,” he said.
On what the price of the device would be, he said: “We are transferring technology as a humanitarian licence as we want the device to reach as many people, which means it will be very affordable. Since we are only a research organisation, we are in talks with manufacturers and will arrive at a cost very soon.” The device will be launched at 12am on August 15.